GLUE
Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
$20.39
+5.37% today
Updated 2026-05-06
Market cap
$1.50B
P/E ratio
—
P/S ratio
12.16x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$4 – $26
Volume
1.1M
WallStSmart proprietary scores
18
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D7.0
Quality
B+2.0
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$32.17
+57.77%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.16x — low leverage
Risks
- Altman Z -0.30 — distress zone
- Thin margins at -31.20%
- Negative free cash flow $-43.78M
- Revenue declining -95.40% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $75.62M | $123.67M | $123.67M |
| Net income | $-108.50M | $-135.35M | $-72.70M | $-38.63M | $-46.13M |
| EPS | — | — | — | — | $-0.46 |
| Free cash flow | $-105.38M | $-62.84M | $38.01M | $-27.50M | $-43.78M |
| Profit margin | — | — | -96.14% | -31.23% | -31.20% |
Peer comparison
Smart narrative
Monte Rosa Therapeutics Inc trades at $20.39. Our Smart Value Score of 18/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -0.30, it sits in the distress. TTM revenue stands at $123.67M. with profit margins at -31.20%.
Frequently asked questions
What is Monte Rosa Therapeutics Inc's stock price?
Monte Rosa Therapeutics Inc (GLUE) trades at $20.39.
Is Monte Rosa Therapeutics Inc overvalued?
Smart Value Score 18/100 (Grade F, Strong Sell).
What is the price target of Monte Rosa Therapeutics Inc (GLUE)?
The analyst target price is $32.17, representing +57.8% upside from the current price of $20.39.
What is Monte Rosa Therapeutics Inc's revenue?
TTM revenue is $123.67M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-0.30 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.16x
ROE-16.90%
Beta1.62
50D MA$17.69
200D MA$13.61
Shares out0.08B
Float0.06B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—